Please Wait...

Gregory Klein

Translation skills

Main profile

Gregory Klein, PhD
Director of Medical Imaging

Gregory Klein brings to BioClinica a multi-faceted medical imaging background, with over 20 years of experience in positron emission tomography (PET) instrumentation, reconstruction and quantification techniques. In his current position, Gregory Klein serves as an in-house PET Imaging expert to advise on acquisition and analysis methods for clinical studies using PET, and to explore new methodologies to more fully exploit the potential of molecular imaging for clinical research.

At the Lawrence Berkeley National Laboratory (LBNL) and the Johns Hopkins University, Dr. Klein developed image reconstruction and quantification methodologies for advanced nuclear medicine functional imaging techniques as well as for structural imaging modalities such as MRI and CT with applications to neuroscience, cardiology and oncology. Following his work at LBNL, Dr. Klein served as Director of Cardiovascular Research at QuantifiCare, S.A., a core lab managing image-based endpoints for drug and device clinical trials, and then opened the first U.S. office for QuantifiCare, serving as its President and CEO. Most recently, Dr. Klein served as a Senior Researcher at the University of Washington School of Public Health, where his work focused on comparative effectiveness research and cost effectiveness of PET and MRI diagnostic methods for staging of breast and lung cancer.

Dr. Klein received his Ph.D. in Vision Science from the University of California at Berkeley, his M.S. in Electrical Engineering from the University of Maryland, and his B.S.E.E. from the University of Nebraska. In addition to his experience with traditional 3D medical imaging modalities, Dr. Klein's expertise has included clinical studies using ophthalmologic optical coherence tomography and fundus photography, as well as dermatologic and cosmetic clinical photography.

Authored Publications

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2014 Nov 24. P1-19.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (3 hours ago)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (8 hours ago)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (8 hours ago)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (10 hours ago)
Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will… https://t.co/BX6wzXctMm
bioclinica (3 days ago)
Let's talk oncology clinical trials at #ESMO18 ! Tap the knowledge of medical & scientific experts @bioclinica who'… https://t.co/RlTjGND5Qg
bioclinica (4 days ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner